GIST Cancer Journal Autumn Issue
The Life Raft Group is pleased to announce the release of the third issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to [...]
Flu season is almost here: top ten tips for GIST patients
Flu Season is upon us. It is hard to believe with the Indian summer weather, but before you know it, the temperature will plummet, and the season when flu flourishes will be here. Being exposed [...]
Personalized Medicine: Paradigm of the Future for Cancer Treatment
Personalized or targeted medicine is the paradigm of the future: treatment options customized for individual patients.
Kie Go Turns Knowledge Into Action
In early 2012, I was having gastric discomfort, so I took over-the-counter medication and it seemed to feel better.
What does cancer feel like?
I’ve been struggling to answer that question since I was diagnosed with a rare, malignancy known as gastrointestinal stromal tumor on February 18, 2011. I cannot remember what I am wearing right now without looking [...]
LRG researchers publish ‘cell sleep’ study
Members of the Life Raft Group Research Team continue to publish results of promising studies aimed at finding a cure for GIST. The latest reflects the collaboration that guides its efforts.
Alianza GIST meeting to shape future
The Alianza GIST 2013 meeting in Miami marked an important milestone for GIST advocates as they embarked on a plan to build a self-sustainable organization in Latin America. “We were energized by the meeting and [...]
LRG researchers publish study on DREAM complex – an important regulator of GIST “cell sleep”
A study about the DREAM complex was published in the June issue of Cancer Research by LRG Research Team members Drs. Anette Duensing and Maria Debiec-Rychter.
How ‘Next Generation’ DNA sequencing is changing the landscape of GIST research and diagnosis
During the past dozen years gastrointestinal stromal tumors have emerged from oncologic obscurity and reached center-stage in the development of targeted therapies for solid tumors. Tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, and more recently regorafenib, have proven effective in suppressing the growth of metastatic GIST, allowing patients to live far longer than during the previous era of ineffective chemotherapy.
First GDOL Chicago hits a homerun!
Our first Chicago GIST Day of Learning (GDOL) was a huge success! Over 50 GISTers and their families gathered for a great day of learning, and sharing experiences. It was wonderful to get to meet so many new people and reconnect with old friends.